Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis

Fig. 1

a was adapted from [16], with permission from John Wiley and Sons

Change from baseline in a SBP and b DBP [16, 17]. ABPM ambulatory blood pressure monitoring, CANA canagliflozin, CI confidence interval, DBP diastolic blood pressure, LS least squares, PBO placebo, SBP systolic blood pressure, SE standard error.

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840